Edgar Filing: CYTOKINETICS INC - Form 4

CYTOKINE Form 4 January 03, 2											
FORM Check thi	is box	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									
if no long subject to Section 1 Form 4 or Form 5	6. r	STATEMENT OF CHANGES IN BENEFICIAL OWNERS SECURITIES							2005 average rs per 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type R	Responses)										
1. Name and Address of Reporting Person <u>*</u> GAGE L PATRICK			2. Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [CYTK]				5. Relationship of Reporting Person(s) to Issuer				
(Last) (First) (Middle) 280 EAST GRAND AVENUE			3. Date of Earliest Transaction (Month/Day/Year) 01/02/2014			(Check all applicable) <u>X</u> Director Officer (give title <u>10%</u> Owner Dother (specify below)					
				4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting 				
FRANCISC	O, CA 94080						Person				
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)	Execution any	Execution Date, if ny		4. Securities ansactionAcquired (A) or ode Disposed of (D) 1str. 8) (Instr. 3, 4 and 5) (A) or ode V Amount (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	ort on a separate line	e for each cla	ass of sec	urities bene	ficially owr	ed directly o	or indirectly.				
					Person inform require	ns who res ation cont ed to respo ys a curre	spond to the colle ained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Ar
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Se
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: CYTOKINETICS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		d of	f			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 6.72	01/02/2014		А		22,321		02/02/2014(1)	01/02/2024	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
GAGE L PATRICK 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080	Х						
Signatures							
By: Sharon A. Barbari For: L. Patrick Gage	(01/03/2014					

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

- (1) This option shall vest and become exercisable as to 22,321 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2015.
- (2) This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of \$60,000.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.